Volume 150, Issue 3, Pages (September 2018)

Slides:

Advertisements

Similar presentations

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD

Advertisements

Managing Cancer Pain: Basic Principles and Invasive Treatments

Statistical Considerations for Immunohistochemistry Panel Development after Gene Expression Profiling of Human Cancers Rebecca A. Betensky, Catherine.

International Journal of Surgery

Volume 145, Issue 1, Pages (April 2017)

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Pancreatic cystic neoplasms in real-time EUS

Volume 133, Issue 1, Pages (July 2007)

Volume 1, Issue 1, Pages 6-7 (September 2016)

My Treatment Approach: Pancreatic Cysts

James L. Buxbaum, MD Clinical Gastroenterology and Hepatology

Volume 148, Issue 1, Pages (January 2018)

Rajmohan Murali, Rachel N. Grisham, Robert A. Soslow

Long-term Follow-up of Intraductal Papillary Mucinous Neoplasm of the Pancreas With Ultrasonography Taketo Yamaguchi, Takeshi Baba, Takeshi Ishihara,

Pancreatic mucinous cystic neoplasm defined by ovarian stroma: Demographics, clinical features, and prevalence of cancer Raghuram P. Reddy, Thomas C.

Are patients willing to travel for better ovarian cancer care?

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

Volume 148, Issue 1, Pages (January 2018)

Volume 146, Issue 3, Pages (September 2017)

Volume 154, Issue 3, Pages (February 2018)

A. Melamed, E. J. Diver, A. A. Gockley, E. M. Hinchcliff, L

Intraductal Papillary Mucinous Neoplasms of the Pancreas

Volume 145, Issue 2, Pages (May 2017)

Volume 138, Issue 1, Pages (July 2015)

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Volume 145, Issue 3, Pages (June 2017)

Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008] Douglas.

Volume 141, Issue 1, Pages 2-9 (April 2016)

Volume 144, Issue 2, Pages (February 2017)

Volume 147, Issue 1, Pages 3-10 (October 2017)

The efficacy of mTORC1/2 inhibition on ovarian cancer stem cells

Volume 123, Issue 5, Pages (November 2002)

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

Volume 151, Issue 1, Pages (October 2018)

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Volume 148, Issue 1, Pages (January 2018)

Volume 145, Issue 2, Pages (May 2017)

Volume 130, Issue 3, Pages (September 2013)

Volume 142, Issue 3, Pages (September 2016)

National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence J. Chino, J.R. Foote,

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 147, Issue 2, Pages (November 2017)

Volume 152, Issue 1, Pages (January 2019)

Volume 123, Issue 1, Pages (July 2002)

Volume 143, Issue 2, Pages (November 2016)

The origins of multidisciplinary cancer care

Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Progression of Unresected Intraductal Papillary Mucinous Neoplasms of the Pancreas to Cancer: A Systematic Review and Meta-analysis Sang Hyun Choi, Seong.

Volume 147, Issue 1, Pages (October 2017)

Volume 139, Issue 3, Pages (December 2015)

Volume 130, Issue 3, Pages (September 2013)

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Volume 147, Issue 3, Pages (December 2017)

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Volume 130, Issue 3, Pages (September 2013)

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

Volume 142, Issue 3, Pages (September 2016)

Volume 152, Issue 1, Pages (January 2019)

Volume 147, Issue 3, Pages (December 2017)

Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma? L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,

Managing Cancer Pain: Basic Principles and Invasive Treatments

Volume 115, Issue 1, Pages (October 2009)

Volume 153, Issue 3, Pages (June 2019)

Volume 154, Issue 2, Pages (August 2019)

Presentation transcript:

Volume 150, Issue 3, Pages 527-533 (September 2018) Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials Nicola S. Meagher, Klaus Schuster, Andreas Voss, Timothy Budden, Chi Nam Ignatius Pang, Anna deFazio, Susan J. Ramus, Michael L. Friedlander Gynecologic Oncology Volume 150, Issue 3, Pages 527-533 (September 2018) DOI: 10.1016/j.ygyno.2018.07.013 Copyright © 2018 The Authors Terms and Conditions

Fig. 1 a: Hotspot mutation frequencies in mucinous borderline and MO-CUPs * Indicates statistically significant difference between borderline and invasive cases (p < 0.05) b: Immunohistochemistry gene expression patterns in mucinous borderline and MO-CUPs * Indicates statistically significant difference (p < 0.05). Gynecologic Oncology 2018 150, 527-533DOI: (10.1016/j.ygyno.2018.07.013) Copyright © 2018 The Authors Terms and Conditions

Fig. 2 Key mutation frequencies compared with data from AACR GENIE * Indicates statistically significant difference between GENIE dataset compared to this study cohort (p < 0.05). No data available: HER2 amplification, PTEN in appendiceal and pancreas; BRAF in appendiceal. Pancreatic tumors were Intraductal papillary mucinous neoplasm (IPMN). ^n = 240 (Current study, HER2 amplification). Gynecologic Oncology 2018 150, 527-533DOI: (10.1016/j.ygyno.2018.07.013) Copyright © 2018 The Authors Terms and Conditions